ABVX Abivax SA

DGAP-News: Abivax secures EUR 15m non-dilutive financing from Kreos Capital

DGAP-News: Abivax secures EUR 15m non-dilutive financing from Kreos Capital
EN
13/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abivax SA

 PRESS RELEASE

Abivax Publishes Financial Reports with the French and U.S. Securities...

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – April 1, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”),  a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chr...

Martial Descoutures
  • Martial Descoutures

ResearchPool Subscriptions

Get the most out of your insights

Get in touch